Adam Brufsky to Survival Analysis
This is a "connection" page, showing publications Adam Brufsky has written about Survival Analysis.
Connection Strength
0.257
-
A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. Sci Rep. 2019 10 16; 9(1):14863.
Score: 0.076
-
Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast J. 2017 Nov; 23(6):718-722.
Score: 0.065
-
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017 Sep; 59:22-32.
Score: 0.065
-
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. Breast Cancer Res Treat. 2019 Jul; 176(2):321-328.
Score: 0.018
-
Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. Am J Clin Pathol. 2018 Mar 07; 149(4):332-343.
Score: 0.017
-
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2017 Aug; 164(3):649-658.
Score: 0.016